The devil as they say is in the detail and teasing out what oncology clinical trial data really means can be challenging for the best of us.

In this post we take a look at several trials  reported out at ASCO24 and consider some of the nuances around the data, in particular what cancer new product professionals may need to think about in order to have an informed opinion.

For some, the data is a bridge over troubled waters, while for others the results were perhaps a bridge too far…

To learn more from our latest oncology review and get a heads up on key cancer research insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by